Key result
PRAISE-AF tests adjunctive renal denervation with pulsed field ablation for persistent AF.
Why the study?
Recurrence rates after catheter ablation for persistent AF remain substantial, and the efficacy of combining pulsed field ablation with renal denervation in this population is unknown.
RCT (n=86)
Patient-blinded
1:1
No
Answers are grounded in this paper and cite their sources.
Renal denervation added to pulsed field ablation in persistent AF should not yet change practice; PRAISE-AF will test this hypothesis.
BACKGROUND: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide and is associated with increased risks of stroke, heart failure, hospitalization, disability, and mortality. Catheter ablation has become an established rhythm-control strategy for symptomatic AF; however, the recurrence rate after ablation remains substantial, especially in patients with persistent AF. Pulsed field ablation (PFA) is an emerging nonthermal ablation technology with myocardial tissue selectivity and a potentially improved safety profile compared with conventional thermal ablation. Renal denervation (RDN) reduces sympathetic nervous system activity and has shown promising effects in reducing AF recurrence when combined with catheter ablation, mainly in patients with paroxysmal AF and hypertension. Whether RDN combined with PFA improves rhythm outcomes in patients with persistent AF remains unknown. TRIAL DESIGN: This is a single center, prospective, randomized, patient-blinded, sham-controlled pilot exploratory trial. A total of 86 patients with symptomatic persistent AF undergoing first-time catheter ablation will be enrolled and randomly assigned in a 1:1 ratio to receive either PFA combined with RDN or PFA combined with a sham RDN procedure. Antiarrhythmic drugs (AADs) will be discontinued after the index procedure in both groups. The primary endpoint is freedom from documented atrial tachyarrhythmia recurrence, including AF, atrial flutter, or atrial tachycardia lasting more than 30 seconds, within 12 months after a single ablation procedure without AADs. Secondary endpoints include freedom from atrial tachycardia recurrence within 3 months, AF burden, blood pressure changes, and major adverse cardiovascular events. Safety endpoints include cardiac, vascular, renal, and other procedure-related adverse events. CONCLUSIONS: This trial will assess the safety and efficacy of PFA with RDN in a postablation contemporary persistent AF patient population. TRIAL REGISTRATION: ClinicalTrials.gov:NCT07320768.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) conducted an RCT in Persistent Atrial Fibrillation (n=86). Pulsed field ablation combined with renal denervation vs. Pulsed field ablation combined with a sham renal denervation procedure was evaluated on Freedom from documented atrial tachyarrhythmia recurrence (AF, atrial flutter, or atrial tachycardia lasting more than 30 seconds) within 12 months after a single ablation procedure without AADs. The PRAISE-AF trial will randomize 86 patients with persistent atrial fibrillation to pulsed field ablation with or without renal denervation to assess 12-month freedom from arrhythmia recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: